Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis

Clin Colorectal Cancer. 2014 Dec;13(4):260-3. doi: 10.1016/j.clcc.2014.09.003. Epub 2014 Sep 21.

Authors

Stefania Gori¹, Gianluigi Lunardi¹, Alessandro Inno², Roberto Magarotto¹, Simona Duranti¹, Michele Giuseppe Messa³, Claudio Mucchino⁴, Massimo Cirillo¹

Affiliations

¹ Medical Oncology Department, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy.
² Medical Oncology Department, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy. Electronic address: alessandro.inno@sacrocuore.it.
³ Nephrology and Dialysis Unit, Azienda Ospedaliera Universitaria, Verona, Italy.
⁴ Chemistry Department, Università degli Studi di Parma, Parma, Italy.

PMID: 25314931
DOI: 10.1016/j.clcc.2014.09.003

No abstract available

Keywords: Dose reduction; FLOX; FOLFOX; Free platinum; Hemodialysis.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / complications
Adenocarcinoma / drug therapy*
Adenocarcinoma / pathology
Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Colorectal Neoplasms / complications
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / pathology
Dose-Response Relationship, Drug
Fluorouracil / administration & dosage
Humans
Kidney Failure, Chronic / etiology
Kidney Failure, Chronic / therapy*
Leucovorin / administration & dosage
Male
Middle Aged
Neoplasm Recurrence, Local / complications
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Organoplatinum Compounds / administration & dosage
Oxaliplatin
Pelvic Neoplasms / complications
Pelvic Neoplasms / drug therapy*
Pelvic Neoplasms / secondary
Prognosis
Renal Dialysis*
Time Factors

Substances

Organoplatinum Compounds
Oxaliplatin
Leucovorin
Fluorouracil